Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial

被引:3
|
作者
Fogacci, Federica [1 ]
Giovannini, Marina [1 ]
Di Micoli, Valentina [1 ]
Grandi, Elisa [1 ]
Borghi, Claudio [1 ]
Cicero, Arrigo Francesco Giuseppe [1 ]
机构
[1] Alma Mater Studiorum Univ Bologna, Med & Surg Sci Dept, Hypertens & Cardiovasc Risk Res Unit, I-40100 Bologna, Italy
关键词
butyrate; clinical trial; dietary supplement; NAFLD; postbiotics; DISEASE; MICROBIOME; KINASE; INDEX;
D O I
10.3390/nu16152454
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Postbiotics could exert different metabolic activities in animal models of non-alcoholic fatty liver disease (NAFLD) and in humans affected by metabolic syndrome. This is a randomized, double-blind, placebo-controlled, parallel-group clinical trial that enrolled a sample of 50 Caucasian healthy individuals with NAFLD, defined as liver steatosis, and metabolic syndrome. After a 4-week run-in, the enrolled individuals were randomized to take a food for special medical purposes with functional release, one tablet a day, containing calcium butyrate (500 mg/tablet), zinc gluconate (zinc 5 mg/tablet), and vitamin D3 (500 IU/tablet), or an identical placebo for 3 months. Liver and metabolic parameters were measured at baseline and at the end of the study. No subject experienced any adverse events during the trial. In both groups, a significant decrease in total cholesterol (TC) and triglycerides (TG) plasma levels was observed at the randomization visit vs. pre-run-in visit (p < 0.05). Regarding liver parameters, after treatment, the fatty liver index (FLI) improved significantly vs. baseline values (p < 0.05) and vs. placebo group (p < 0.05) in the active treatment group, and the hepatic steatosis index (HSI) improved significantly vs. baseline values (p < 0.05). Moreover, after active treatment, TC, TG, and gamma-glutamyl transferase (gGT) improved significantly vs. baseline values (p < 0.05), and TC and TG improved vs. placebo group (p < 0.05), as well. In the placebo group, liver parameters remained unchanged after treatment; only TG improved significantly vs. baseline values (p < 0.05). In our study, we observed that the butyrate-based formula improved FLI and plasma lipid patterns in individuals affected by liver steatosis and metabolic syndrome.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial
    Rodriguez-Moran, Martha
    Simental-Mendia, Luis E.
    Gamboa-Gomez, Claudia, I
    Guerrero-Romero, Fernando
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2018, 25 (03) : 261 - 266
  • [2] The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial
    Yari, Zahra
    Movahedian, Mina
    Imani, Hossein
    Alavian, Seyed Moayed
    Hedayati, Mehdi
    Hekmatdoost, Azita
    EUROPEAN JOURNAL OF NUTRITION, 2020, 59 (06) : 2569 - 2577
  • [3] The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial
    Zahra Yari
    Mina Movahedian
    Hossein Imani
    Seyed Moayed Alavian
    Mehdi Hedayati
    Azita Hekmatdoost
    European Journal of Nutrition, 2020, 59 : 2569 - 2577
  • [4] CHOLECALCIFEROL SUPPLEMENTATION AND INFLAMMATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
    Seibert, Eric
    Ulrich, Christof
    Trojanowicz, Bogusz
    Lehmann, Ulrike
    Dierkes, Jutta
    Stangl, Gabriele I.
    Girndt, Matthias
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [5] Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial
    Ranasinghe, Priyanga
    Wathurapatha, Wasundara S.
    Galappatthy, Priyadarshani
    Katulanda, Prasad
    Jayawardena, Ranil
    Constantine, Godwin R.
    JOURNAL OF DIABETES, 2018, 10 (05) : 386 - 397
  • [6] Antioxidant response to artichoke leaf extract supplementation in metabolic syndrome: A double-blind placebo-controlled randomized clinical trial
    Rezazadeh, Khatereh
    Aliashrafi, Soodabeh
    Asghari-Jafarabadi, Mohammad
    Ebrahimi-Mameghani, Mehrangiz
    CLINICAL NUTRITION, 2018, 37 (03) : 790 - 796
  • [7] The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Alidadi, Mona
    Sahebkar, Amirhossein
    Eslami, Saeid
    Vakilian, Farveh
    Jarahi, Lida
    Alinezhad-Namaghi, Maryam
    Arabi, Seyed Mostafa
    Vakili, Saba
    Tohidinezhad, Fariba
    Nikooiyan, Yasaman
    Norouzy, Abdolreza
    PHARMACOLOGICAL PROPERTIES OF PLANT-DERIVED NATURAL PRODUCTS AND IMPLICATIONS FOR HUMAN HEALTH, 2021, 1308 : 1 - 11
  • [8] Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial
    Asemi, Zatollah
    Karamali, Maryam
    Esmaillzadeh, Ahmad
    MOLECULAR NUTRITION & FOOD RESEARCH, 2014, 58 (07) : 1465 - 1473
  • [9] Metabolic response to folate supplementation in overweight women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial
    Samimi, M.
    Asemi, Z.
    Karamali, M.
    Foroozanfard, F.
    Esmaillzadeh, A.
    HUMAN REPRODUCTION, 2014, 29 : 5 - 6